Lysosome-associated membrane glycoprotein (LAMP)--preliminary study on a hidden antigen target for vaccination against schistosomiasis by Nawaratna, Sujeevi S K et al.
Lysosome-associated membrane glycoprotein (LAMP)--
preliminary study on a hidden antigen target for vaccination
against schistosomiasis
Nawaratna, S. S. K., Gobert, G. N., Willis, C., Mulvenna, J., Hofmann, A., McManus, D. P., & Jones, M. K.
(2015). Lysosome-associated membrane glycoprotein (LAMP)--preliminary study on a hidden antigen target for
vaccination against schistosomiasis. Scientific reports, 5, 15069. DOI: 10.1038/srep15069
Published in:
Scientific reports
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2015 the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article
are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
1Scientific RepoRts | 5:15069 | DOi: 10.1038/srep15069
www.nature.com/scientificreports
Lysosome-associated membrane 
glycoprotein (LAMP) – preliminary 
study on a hidden antigen 
target for vaccination against 
schistosomiasis
Sujeevi S. K. Nawaratna1,2, Geoffrey N. Gobert2, Charlene Willis2, Jason Mulvenna2, 
Andreas Hofmann3,4, Donald P. McManus2 & Malcolm K. Jones1,2
Our previously reported gene atlasing of schistosome tissues revealed transcripts that were highly 
enriched in the digestive tract of Schistosoma mansoni. From these, we selected two candidates, 
Sm-LAMP and Sm-NPC2 for testing as vaccine targets. The two molecules were selected on the basis 
of relatively high expression in the gastrodermis, their potentially important biological function, 
divergence from homologous molecules of the host and possible apical membrane expression in the 
gastrodermis. Bacterially expressed recombinant peptides corresponding to regions excluding trans-
membrane domains of the selected vaccine targets were used in blinded vaccine trials in CBA mice 
using alum-CpG as adjuvant. Vaccine trials using the recombinant insoluble Sm-LAMP protein showed 
16–25% significant reduction in total worm burden. Faecal egg count reduction was 52% and 60% in 
two trials, respectively, with similar results for the solubly expressed protein. Liver egg burden was 
reduced significantly (20% and 38%) with an insoluble recombinant Sm-LAMP in two trials, but not 
with the soluble recombinant form. Parasite fecundity was not affected by either Sm-LAMP protein 
preparations in the trials. It is concluded that Sm-LAMP may provide limited protection towards S. 
mansoni infections but could be used in combination with other vaccine candidates, to provide more 
comprehensive protection.
Schistosomiasis, a neglected tropical disease affecting over 200 million people in 76 countries, is caused 
by infection with parasitic flatworms of the genus Schistosoma1. Currently, the only effective treatment 
for all forms of schistosomiasis is the drug praziquantel. Continued use of this single drug may be prob-
lematic for a number of reasons, including the possibility of reduced sensitivity of schistosomes to the 
compound2–5, its lack of efficacy against immature schistosomes6 as well as the lack of protection against 
reinfection. In highly endemic regions, the success of praziquantel can be limited by constant reinfec-
tion. Therefore, there is an urgent need for alternative treatments, including new drugs and vaccines for 
countering the possibility of emerging drug resistance.
Over the years there have been many vaccine candidates tested against Schistosoma infections includ-
ing irradiated whole parasites7–9, whole parasite extracts, recombinant peptides and DNA based vac-
cines10,11. In the 1990’s six antigens were selected by the WHO for further research12, but of these, only 
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fatty acid binding protein (Sm14) and glutathione-S-transferase (Sm28 GST) have reached clinical tri-
als13. Two S. mansoni tetraspanins (TSP 1 and TSP2), which are tegument-associated molecules originally 
uncovered by signal sequence trap methods and tegument proteomic surveys, have shown promising 
vaccine efficacies13,14. Another outer membrane protein of the tegument of S. mansoni, Sm29, is a prom-
ising vaccine target against which putative resistant individuals in endemic settings have developed a 
strong IgG1 and IgG3 isotype response15,16. A recent DNA vaccine against the large subunit of S. man-
soni calpain (Sm-p80) has been tested in mice effectively against both S. japonicum and S. mansoni11. 
Prominent targets of vaccination have been the surface lining of the schistosome parasites, the tegu-
ment13, a primary site of host interaction.
Schistosomes possess a simple gastrovascular cavity for digestion. This blind digestive system consists 
of a mouth, an oesophageal region from which emerges the caecal region, which functions in digestion 
and nutrient absorption. The lining of the caecum is a syncytial epithelium, termed the gastrodermis. The 
schistosome digestive system becomes metabolically active soon after the parasite invades its mamma-
lian host, differentiating and growing at a rate commensurate with the development of the parasite17–19. 
The primary role of the digestive system in blood-feeding schistosomes is to process large quantities 
of ingested blood. Adult female parasites are thought to process 330,000 erythrocytes per hour20. The 
schistosome gut is thus exposed to host blood and a variety of immune components soon after host 
invasion, possibly as early as two days after entering the liver21. Molecules expressed at the surface of 
the schistosome gastrodermis may provide good targets as vaccine candidates due to their location and 
importance in nutritional support of the parasite.
Molecules expressed at the surface of the schistosome gastrodermis are not naturally exposed to 
the host immune system in parasitism because they are secluded within the parasite. Some gastroder-
mal molecules are exposed to the host as vomitus or during disintegration after the worm’s death22. 
Consequently, the parasite is not under evolutionary pressure to develop mechanisms to evade the host 
immune response against these “hidden” molecules23. We reasoned that some molecules putatively 
bound at the surface of the gastrodermis may be targets for vaccination, in much the same way as hidden 
antigens of the sheep nematode, Haemonchus contortus24,25 and the cattle tick Rhipicephalus microplus26 
have been targeted.
Here, we outline a pipeline of antigen discovery and testing in vaccination experiments. Although our 
study is not the first to test schistosome gut molecules as vaccine targets, our approach incorporates the 
identification of molecules enriched in the gastrodermis, a rigorous approach to antigen selection lead-
ing to functional characterisation and testing of candidate molecules as targets of immune prophylaxis. 
We focus on two antigens, a schistosome lysosome-associated membrane glycoprotein (Sm-LAMP) and 
Niemann Pick type C2 protein (Sm-NPC2). This approach represents a new alternative for Schistosoma 
vaccine discovery.
Results
Selection of antigens. We previously reported that 393 genes were up-regulated in the gastrodermis 
of adult female worms of S. mansoni compared with whole female parasite tissue27. Blast2GO analysis 
provided specific annotations and descriptions for 126 genes and gene products. The main characteris-
tics used in the selection of genes for vaccine trials are summarised in Supplementary Table 1. Of the 
126 annotated genes transcripts that were enriched in the gastrodermis of S. mansoni28, 23 had putative 
orthologues that were also up-regulated in the gastrodermis of S. japonicum29. The genes were then 
scrutinised for the following criteria: enrichment in the gastrodermis relative to other tissues, important 
biological function, motifs consistent with membrane association and sufficient sequence divergence 
from human and mouse (host) orthologues (Fig. 1, Supplementary Fig. 1). Of these 23 genes, two targets 
were selected, namely a LAMP (enriched 2.7-fold in S. mansoni, 46-fold in S. japonicum) and a Niemann 
Pick type C2 protein (Sm-NPC2) (3.1-fold in S. mansoni, 120 fold in S. japonicum). ClustalW multiple 
sequence alignments were used to calculate the percentage identity of the two selected vaccine targets 
with homologous sequences from human and murine hosts. Sm-LAMP had only 13% and 15% sequence 
identity with human LAMP 1 and 2, respectively. Mouse LAMP 1 and 2 had sequence identities of 14% 
and 15% to Sm-LAMP, respectively. Sm-NPC2 sequence had 32% identity to human and 31% to mouse 
NPC2.
Real-time PCR. The relative transcript abundance of Sm-NPC2 and Sm-LAMP was investigated for a 
range of life cycle stages of S. mansoni, and in different biologically important tissues of the S. mansoni 
adult female (Fig. 2). Both Sm-NPC2 and Sm-LAMP were enriched in schistosomula and adult male and 
female worms, that is, in stages associated with human parasitism.
Protein expression. Appraisal of Sm-LAMP recombinant protein structure. The amino acid sequence 
of Sm-LAMP was analysed using the PSIPRED v3.0 secondary structure prediction algorithm30. The pre-
dicted structure suggested that the schistosome molecule consists of 24% beta-strands and 76% unstruc-
tured regions (Fig.  3). The CD spectrum of soluble Sm-LAMP showed excellent agreement with the 
expected secondary structure content, and fits using three Fasman prototype structural elements (helix, 
strand, random) yielded 8% alpha-helix, 16% beta-strand and 75% unstructured regions (Fig. 4).
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Western blots. Rabbit polyclonal antisera in 1:500 dilutions were able to detect the recombinant proteins 
and native proteins in the soluble worm antigen preparation (SWAP) and insoluble protein (IS) fractions 
of worm homogenates. Sm-LAMP and Sm-NPC2 were detected in both SWAP and IS (Fig. 5). Sm-LAMP 
is present as a 64 kDa band in Western blot analysis which is double the size expected (33.6 kDa). Mass 
spectrometry fingerprinting after limited proteolysis performed on these gel bands confirmed the protein 
as Sm-LAMP.
Immunolocalisation. Immunolocalisation studies showed that all three proteins were localised to the 
gastrodermis and tegument of adult male and female parasites (Fig. 6).
Endotoxin levels. Preparations of soluble Sm-LAMP presented endotoxin levels of 6.95 EU/ml, whereas 
preparations of insoluble Sm-LAMP and Sm-NPC2 contained endotoxin levels of 8.48 and 9.54 EU/ml, 
respectively.
Figure 1. Comparison of S. mansoni LAMP with human and mouse LAMP1 and LAMP2 using 
ClustalW. Sm-LAMP was compared with mouse and human orthologues and other schistosome LAMP 
proteins. The tree shows that the schistosome molecules clearly bifurcate from mammalian counterparts.
Figure 2. Differential expression of Sm-NPC2 and Sm-LAMP throughout the S. mansoni lifecycle stages 
and in different biologically important tissues of the S. mansoni adult female. 
www.nature.com/scientificreports/
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Figure 3. Sequence of Sm-LAMP recombinant protein with C terminal hexa-histidine tag. Areas marked 
in red show the predicted beta strands.
Figure 4. CD spectra analysis of soluble Sm-LAMP recombinant protein in 20 mM NaCl, 10 mM 
Na2HPO4 at pH 8.0. The experimental data (red) fit well with the predicated Fasman fit (blue).
Figure 5. Western blots performed with the rabbit polyclonal antibodies. Rabbit plyclonal antibodies 
made against Sm-LAMP (a) and Sm-NPC2 (b) were used against the respective recombinant protein (lanes 2 
and 3), SWAP (lane 4) and insoluble fraction of the crude worm protein extract (lane 5). Lane 1- molecular 
weight markers.
www.nature.com/scientificreports/
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Vaccine trials. The results of two vaccine trials (trial one with insoluble protein and trail two with sol-
uble protein) are shown in Fig. 7 and Table 1. In the first vaccine trial, statistically significant reductions 
in egg and worm counts were obtained only with Sm-LAMP. The mean female worm count reduction 
was 20.93% (p < 0.05), whereas the total worm burden reduction was 16.21% (p < 0.05) (Fig. 7(a,b)). The 
mean percentage egg count reductions in faeces, liver and intestinal tissue were 51.9% (p = 0.001), 20% 
(p < 0.05) and 21% (p < 0.05), respectively (Fig. 7(c–e)). There was a significant reduction in the mature 
egg percentage in the intestinal wall for the Sm-LAMP (21%) and Sm-NPC2 (34%) vaccine groups 
with an increase in the percentage of immature eggs in the total egg population (Fig. 7(f,g)). However, 
Sm-NPC2 did not produce any significant protection in terms of reduced worm numbers nor reduced 
numbers of faecal, liver or intestinal eggs. The second vaccine trial resulted in significant worm burden 
and egg count reduction in the group immunised with the insoluble Sm-LAMP (Fig. 7(h,i)). Percentage 
egg reduction in liver, intestine and faeces (38%, 49% and 60%, respectively) showed reproducible results 
with that of the first vaccine trials for insoluble Sm-LAMP. Total and female worm counts also showed 
significant reduction (25% and 35.7%) when using the insoluble Sm-LAMP protein. However, the vac-
cine group immunised with soluble Sm-LAMP did not show any significant reduction in worm counts or 
egg counts. No significant reduction was observed in the percentage of mature eggs in oograms in either 
of the groups in the second vaccine trial with only 4% reduction in the group immunised with insoluble 
Sm-LAMP protein. Soluble Sm-LAMP showed a significant reduction in liver granuloma area (p = 0.003) 
when compared to the control group. There was no significant difference between the average lengths of 
male and female worms from vaccinated mice and the control mice in both vaccine trials. Table 1 shows 
a comparison of the results of the two vaccine trials for Sm-LAMP. The control groups of mice in both 
vaccine trials did not show any antibody response. Antibody response to IgG subtypes was greater for 
soluble antigen than the insoluble form except for IgG2a (Table 1).
Discussion
LAMP is a major integral protein of the lysosomal membrane31, which plays an important role in the 
formation of phagosomes32. LAMP-2 has also been found to be involved in cholesterol transport33,34. 
LAMPs are characterised by abundant N-terminal glycosylation sites, a single transmembrane domain 
and a short cytosolic tail35,36. Sm-LAMP has four cystine residues of which one is conserved as compared 
to human, mouse, S. japonicum (Sjp_0002430) and other S. mansoni LAMP proteins (Smp_073400, 
Smp_032520, Smp_039620). The transmembrane region is also conserved when compared with human, 
mouse and other schistosome LAMPs (Supplementary Fig. 1). Sm-LAMP contains a lysosomal targeting 
signal (YXXØ , where X could be any amino acid and Ø is a bulky hydrophobic residue)37 in its cyto-
solic tail (YTTL) (Supplementary Fig 1). Interestingly, some members of the LAMP family have also 
been described as proteins expressed at the cell surface38,39. In our transcriptomic studies27 Sm-LAMP 
(Smp_162770) was shown enriched in the gastrodermis of females29. Other workers found the protein in 
the vomitus of adult worms22. These observations indicate that the molecule is abundant in the gut and 
potentially located at or near the surface of the gastrodermis27. Further, the presence of Sm-LAMP in 
the vomitus and cell membranes might explain why the protein appears in soluble adult worm antigen 
preparation (SWAP) and insoluble protein fractions of the worm.
NPC2 homologues are known as lysosomal molecules. We found Sm-NPC2 to be highly enriched in 
the gastrodermis of S. mansoni and S. japonicum28,29. Sm-NPC2 is also enriched in the S. mansoni ovary, 
an observation consistent with the detection of abundant NPC2 in the secretome of S. mansoni eggs40. 
NPC2 functions with NPC1 in the transport of cholesterol, glycolipids and other sterols in eukaryotic 
lysosomes41,42. In mice, NPC2 expression correlates with a cellular requirement for cholesterol, being 
abundant in tissues that use this sterol, such as the ovary and uterine cells, but not the oviduct43. A 
secretory form of NPC2 is also found in the gut lumen of mammals, where it may be involved in 
Figure 6. Immunofluorescence of S. mansoni female worm sections. Rabbit plyclonal antibodies made 
against Sm-LAMP and Sm-NPC2 antibodies were used in the two sections respectively. Rabbit pre-immune 
sera were used for the negative control.
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enhancing solubilisation of dietary cholesterol44,45. Similarly, Sm-NPC2 has been found in S. mansoni 
vomitus, implicating this molecule in surface expression and secretion by the gastrodermis22.
As discussed above, the two vaccine candidates we selected are membrane-resident molecules pos-
tulated to be related to cholesterol/lipid metabolism. Many eukaryote pathogens scavenge the majority 
of their nutrients including lipid and cholesterol46. Likewise, schistosomes lack the ability to synthesise 
sterols and lipids47 and, therefore, obtain these molecules from the host to meet their requirements46,48,49. 
Molecules related to cholesterol uptake and metabolism are likely to be important for schistsome sur-
vival within the mammalian host. As schistosomes are dependent on the human host for sterol and lipid 
requirements47, this is an additional advantage for the selected vaccine candidates in addition to being 
present as a hidden antigens.
Only Sm-LAMP reduced worm burdens, although the protection was moderate compared with other 
Schistosoma vaccine candidates10,14,50. Sterile immunity is not required from a schistosome vaccine51,52. 
Although there was significant worm count reduction in the mice immunised with Sm-LAMP, the num-
ber of eggs per female was not reduced. Therefore the egg count reductions were due to the reduction 
Figure 7. Comparison of worm counts and egg counts between the two vaccine trials. Percentage 
reduction is shown above each group where a significant reduction in numbers was observed. Error bars 
represent the standard error (n = 10). *p < 0.05. All graphs were created using GraphPad Prism 6.
www.nature.com/scientificreports/
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of the number of female worms, and not an effect on fecundity of individuals. In contrast, the oogram 
showed that the percentage of mature eggs reaching the intestine was reduced significantly, suggesting 
an effect on egg development. The higher reduction in faecal eggs, when compared to liver and intestinal 
egg counts, may also be due to the reduced number of mature eggs in the intestinal wall. The significant 
reduction of the liver granuloma area by Sm-LAMP shows that this vaccine candidate could result in a 
significant clinicopathological improvement of the host.
The soluble form of Sm-LAMP did not provide better vaccine efficacy but it resulted in a similar 
level of faecal egg reduction compared with the insoluble protein. Conversely, the ELISA results showed 
that the antibody response was slightly higher with the soluble protein. We tested mouse serum for the 
IgG response only. In humans, protein antigens commonly induce an IgG1 or IgG3 response (IgG2a 
and IgG2b mouse equivalent)53 but can also generate IgG4 (mouse IgG1) or IgE. Our results showed a 
better IgG2b and IgG1 response with the soluble protein antigen which conforms to the above pattern. 
This could be explained by the physico-chemical nature of the soluble antigen which may have better 
antigenic epitopes due to the protein adopting a native fold. However, the insoluble antigen showed a 
better response with the IgG2a subclass. Although ELISA analysis showed that the antibody response was 
better against the soluble protein, this correlation may not predict its complete protective effectiveness in 
vivo54. Therefore, antibodies raised against the soluble proteins could result in less protection (ie worm 
elimination) than those produced against insoluble protein. Future studies addressing the IgE response 
will be required to assess whether these may have contributed to the better protection observed with the 
insoluble antigen. Notably, there was a correlation between the IgE levels and the degree of protection 
against the Schistosoma infection in resistant individuals55 and a balanced Th1 and Th2 type response 
has been associated with better protection against the infection. Therefore the higher protection level 
observed with the insoluble protein might be due to a better balance in Th1/ Th2 response.
Sm-NPC2 was ineffective as a vaccine candidate. Although Sm-NPC2 was predicted to be present 
on the apical membrane of the gastrodermis and in silico analysis predicted good antigenicity, the true 
accessibility of antibodies specifically directed against these proteins may be poor in the gastrodermis. 
Accessibility is considered an obstacle in designing vaccines against outer tegument proteins because of 
the presence of the parasite’s membranocalyx52. Although the gastrodermis is not lined by a membrano-
calyx, other factors might have come into play to limit efficacy, among them limited accessibility of the 
molecule due to its location in the gastrodermal cytoplasm or the structure of the protein itself52. Also, 
the removal of transmembrane regions from the recombinant peptide may have had an effect on the final 
structure of the recombinant protein.
In conclusion, the use of proteins from the apical membranes of the gastrodermis is a possible ave-
nue for selection of better vaccine candidates against schistosomiasis. Out of the two vaccine candidates 
selected in this study Sm-LAMP gave a reproducible moderate level of vaccine efficacy, whilst Sm-NPC2 
cannot be recommended as a vaccine target. However, for the purpose of this study, Sm-NPC2 was a 
useful positive control, especially in mitigating any possible effect that may have arisen from bacte-
rial endotoxin contaminations which were found to be similar for both proteins in the two vaccine 
trials. Sm-LAMP efficacy could be enhanced by investigating smaller peptides, using in combination 
with another moderate efficacious vaccine candidate or with praziquantel treatment. The presence of 
Antibody end point titres
Vaccine trial 1 Vaccine trial 2
Insoluble LAMP Insoluble LAMP Soluble LAMP
IgG 1:32 000 (1:100) 1:128 000 (1:100) 1:256 000 (1:100)
IgG1 1:128 000 (1:100) 1: 32 000 (1:100) 1:256 000 (1:100)
IgG2a 1:64 000 (1:50) 1:128 000 (1:50) 1:64 000 (1:50)
IgG2b 1:128 000 (1:50) 1:32 000 (1:50) 1:128 000 (1:50)
IgG3 NR NR 1:64 000
Worm counts
Females -% reduction 20.93 (p = 0.04) 35.7 (p = 0.019) 16 (NS)
Total -% reduction 16.21 (p = 0.04) 25 (p = 0.01) 8.7 (NS)
Egg counts
Liver -% reduction 20 (p = 0.021) 38 (p = 0.015) 13 (NS)
Intestine -% reduction 21 (p = 0.011) 49 (NS) 30 (NS)
Faecal -% reduction 51.9 (p = 0.001) 60 (p = 0.009) 54 (p = 0.035)
Faecal egg reduction per 
female 56.2 (NS) 22.3 (NS) 58.6 (NS)
Table 1.  Summary of key results for vaccine trials for Sm-LAMP. The antibody titres in brackets show the 
control values. NR = No response. NS = No statistical significance.
www.nature.com/scientificreports/
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the antibodies to Sm-LAMP and Sm-NPC2 should be tested in putative resistant individuals (endemic 
normals) to confirm the true hidden nature of these targets. However, the absence of a response in the 
negative control group of mice in the vaccine trial supports our theory of the two vaccine targets being 
hidden from the host. Targeting antigens occurring upstream from the gastrodermis56–58, including the 
secreted components of the oesophageal gland region, may prove to be a better strategy. Although a 
relatively small tissue mass, the oesophageal gland appears as a highly metabolically active region in 
the initial processing of the host blood meal and, as such, contains many potential vaccine candidates. 
Molecules expressed in the oesophageal gland may then represent better hidden antigen targets since the 
antibodies generated there would be less exposed to digestive proteases of the worm, and additionally, 
this region develops earlier in the young worm. These antigens could be combined in the future for better 
hidden antigen vaccines. Therefore we conclude that Sm-LAMP provides marginal protection towards 
S. mansoni infections and has the potential to be used in combination with other vaccine candidates or 
with praziquantel treatment, to provide more comprehensive protection against schistosomasis.
Materials and Methods
Ethics Statement. Use of animals was approved by the Animal Ethics Committee of the QIMR 
Berghofer Medical Research Institute under project P1289. The study was conducted according to 
the guidelines of the National Health and Medical Research Council of Australia, as published in the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 7th edition, 2004 
(www.nhmrc.gov.au). All work related to live lifecycle stages was performed in quarantine-accredited 
premises.
Selection of hidden antigens. Selection of antigens for this work followed extensive transcriptional 
profiling of individual tissues we previously reported for Schistosoma mansoni27. Genes enriched in the 
gastrodermis, with expression profiles 2 fold or higher, as compared to expression in the entire female 
worm, were further filtered in silico for the selection of potential targets as described below.
The annotations of all 393 up-regulated genes of the gastrodermal tissue were updated using Blast2GO 
software59. The annotation consisted of gene descriptions, gene ontologies and InterPro Scan results. 
Sequences were analysed for inferred membrane association (transmembrane domain), high expression 
in S. mansoni and S. japonicum27,29 gastrodermal tissues, and a biological function considered essential 
and potentially non-redundant. Additionally, the antigenicity and hydrophobicity of the peptides were 
predicted using MacVector™ 8.0 software (http://www.macvector.com) (Supplementary Fig. 2). From a 
panel of potential targets, two molecules, LAMP and a homologue of the Niemann Pick type C2 protein 
(NPC2) protein (Smp_194850) were chosen for further characterization and vaccine efficacy trials. The 
similarity of candidate molecules was assessed by comparing their amino acid sequences to those of 
human and mouse orthologues using ClustalW2 online alignment tool60. Sm LAMP is also compared to 
the three other LAMP proteins described in the Schistosoma Gene Database. A phylogenetic tree was 
drawn using Phylogeny.fr to compare Sm-LAMP with other schistosome, human and mouse orthologs.
Real-time PCR. Relative abundance of the Sm-LAMP and Sm-NPC2 transcripts was determined for 
different S. mansoni life cycle stages (eggs, miracidia, cercariae, 5 day old schistosomula, adult males and 
adult females) and for microdissected digestive and reproductive tissues27 using quantitative real-time 
PCR (qPCR), to confirm that the selected genes are enriched in the gastrodermis and in life cycle 
stages within the mammalian host27. Forward and reverse primers (Sigma-Aldrich) were designed for 
Sm-LAMP and Sm-NPC2 using Primer3 (v.0.4.0) software (Supplementary Table 2). Total RNA samples 
were DNase treated (Promega) prior to synthesis of cDNA using a QuantiTect® Whole Transcriptome 
Kit (QIAGEN). All cDNA samples were diluted to 5 ng/μ l. Real-time PCR was performed and analysed 
using previously described protocols61 using DNA segregation ATPase62 (Accession No. Smp176580) as 
the normalising housekeeping gene. Data were analysed using the Rotor Gene 6 software63.
Protein expression. Cloning. The predicted extra-cellular Sm-LAMP sequence consisting of 296 
amino acids, with the removal of the less antigenic region adjacent to the transmembrane region (as 
predicted by MacVector™ 8.0 software) (Supplementary Fig. 2) was amplified by PCR from cDNA of S. 
mansoni adult female worms using the forward primer with a Nco1 restriction enzyme recognition site 
(in lowercase in the following sequence), catgccatggcgATGTTGCCAGGTAGCTCAGTTTATATTG and 
the reverse primer with a Xho1 enzyme recognition site (in lower case) ccgctcgagCGGAAATAAAT-
TCTTATCCATATAATAAG with PfuTurbo® DNA polymerase (Agilent-Stratagene). The PCR product 
and the pET− 28a (+ ) (Novagen) vector were digested (Nco1-HF and Xho1, New England BioLabs) and 
then dephosphorylated using CIP (FINNZYMES, Thermo Scientific). The products were purified by PCR 
using QIAquick® PCR Purification kit (QIAGEN), according to the manufacturer’s instructions, and then 
ligated (T4DNA Ligase (Promega) into the vector.
Sm-NPC2, cloned into pET100/D-TOPO® vector, was kindly provided by Dr. David L. Williams, 
Department of Immunology-Microbiology, Rush University, Chicago, Illinois.
The ligation mixture was added to One Shot® TOP 10 (Invitrogen) chemically competent E. coli cells 
and transformed by heat shock, followed by the addition of LB medium. Transformed cells were then 
plated onto LB agar plates containing 50 μ g/ml Kanamycin sulphate and incubated overnight at 37 °C. 
www.nature.com/scientificreports/
9Scientific RepoRts | 5:15069 | DOi: 10.1038/srep15069
LB agar plates containing 100 μ g/ml Ampicillin were used for growing pET100/D-TOPO® vector with 
Sm-NPC2.
Ten single colonies per construct were screened for the presence of an insert using PCR with T7 
(pET) promoter TAATACGACTCACTATAGGG and terminator CTAGTTATTGCTCAGCGGTG prim-
ers (Sigma-Aldrich). Colonies with confirmed inserts were grown overnight in 5 ml of LB medium with 
antibiotics. Plasmids were purified using the QIAprep® Spin Miniprep kit (QIAGEN) using a micro-
centrifuge. Clones were sequenced using Big Dye Terminator v3.1 (Amersham Bioscience, Australia) 
sequencing protocol to confirm the insert was in frame and did not contain any mutations.
Protein production and purification. For each protein, a plasmid containing the correct, in-frame 
sequence was transformed into BL 21-(DE3) cells (Invitrogen) via heat shock as described above.
Cells from an overnight culture were used to inoculate 1 L of 2YT medium with appropriate anti-
biotic. Cultures were incubated in a shaker incubator until an OD600 ≈ 0.6 was reached and induced 
with  mM IPTG. For inclusion body production, expression was carried out at 37 °C for 5 hours. After cell 
harvest, lysis and separation of debris, the inclusion bodies were solubilised using a buffer containing 6 M 
guanidine hydrochloride and 20 mM beta-mercaptoethanol (BME) at room temperature for one hour. 
Solubilised Sm-LAMP was then purified using HIS-Select® Nickel affinity Gel (Sigma). A buffer contain-
ing 6 M urea and BME with varying concentrations of imidazole was used for elution. An Amicon Ultra-
15 centrifugal filter device with a 10 kDa cutoff was used to concentrate the eluted protein. Imidazole 
and urea were removed by dialysing the concentrated protein against 1× PBS using Snake Skin® pleated 
dialysis tubing with a 10 kDa cutoff (Thermo Fisher Scientific).
For Sm-LAMP, soluble protein was obtained after modification of the above procedure such that 
expression was carried out at 16 °C for 24–28 hours. After cell lysis and removal of debris by centrifug-
cation, soluble protein was purified from the cytosolic contents using affinity chromatography as above, 
but without urea and BME.
All purified recombinant proteins were identified by Western blot with anti-His antibodies, as well 
as mass spectrometry fingerprinting after limited proteolysis. Endotoxin contamination of recombi-
nant proteins was measured using Pierce LAL (Limulus Amebocyte Lysate) Chromogenic Endotoxin 
Quantitation Kit (Thermo Fisher Scientific Inc., IL, USA) according to the manufacturer’s instructions. 
All proteins used for vaccinations were tested at similar concentrations.
Appraisal of Sm-LAMP recombinant protein structure. The secondary structure of solubly expressed 
Sm-LAMP was assessed by acquiring CD (circular dichroism) spectrum of 3 mM Sm-LAMP in 20 mM 
NaCl, 10 mM Na2HPO4, pH 8.0 acquired on a Jasco J-715 CD/ORD spectropolarimeter. The data were 
fitted with Fasman standard curves using the software program ACDP64 to determined secondary struc-
ture content. These results were compared to secondary structure contents predicted by PSIPRED v3.030.
Rabbit polyclonal sera. Rabbit polyclonal antibodies were produced commercially at the Institute of 
Medical and Veterinary Sciences (IMVS), Veterinary Services Division, Gilles Plains South Australia 
5086. Each rabbit received 1.2 mg of insoluble protein with Freund’s adjuvant, in four doses (0.3 mg per 
dose) at 0, 3, 6 and 9 weeks. All sera were aliquoted and stored at − 80 °C until further use.
Western blot. Rabbit polyclonal antisera were used to detect the presence of Sm-LAMP and Sm-NPC2 
in a S. mansoni soluble worm antigen preparation (SWAP) and in the insoluble fraction. Fifty nanograms 
of protein (50 ng recombinant protein, SWAP and insoluble protein) were run in a SDS- PAGE and 
transferred onto a PVDF membrane, which had been soaked in 100% methanol and rinsed with sterile 
milliQ water. The membrane was incubated with Odyssey® blocking buffer (LI-COR® Biosciences) for 
1 hour at room temperature. Specific primary rabbit polyclonal antibodies were added at 1:500 dilutions 
with Odyssey blocking buffer. Goat anti-rabbit IRDye® 800 CW (LI-COR® ) secondary antibody was 
used at 1:15,000 dilution in Odyssey blocking buffer and detection was by ODYSSEY imaging system 
(LI-COR® ).
Immunolocalisation. Freshly perfused S. mansoni worm pairs were fixed in 75% acetone and 25% eth-
anol at RT for 5 min. OCT blocks containing 30 worm pairs each were stored at − 80 °C until sectioned. 
Frozen sections (7 μ m thick) were cut onto SuperFrost® glass slides (MENZEL-GLÄSER) and stored 
at − 80 °C until needed. Sections were thawed and rehydrated before blocking with 5% goat serum, 
5% FBS and 2% BSA in PBS. Sections were then incubated for 1 hour in primary antibody (against 
Sm-LAMP and Sm-NPC2) diluted 1:200 in the blocking buffer, washed and then secondary antibody, 
goat anti-rabbit Alexa Flour® 488 (Invitrogen) was added after diluting 1:100 in blocking buffer. Sections 
were mounted in ProLong® Gold Antifade agent with DAPI (Invitrogen) after 3 washes in PBS. Sections 
were protected from light until examination by fluorescence microscopy using a Leica DMIRB Inverted 
research microscope.
Vaccine trials. Groups of ten, eleven week old female CBA mice were used in blinded vaccine trials 
(Fig.  8). Each mouse was vaccinated with three doses of 25–30 μ g of recombinant protein/PBS com-
bined with an equal volume of Aluminium Hydroxide gel (alum) (Sigma) and 10 μ g of CpG ODN1826 
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(InvivoGen) at two weekly intervals. The control group was given PBS and adjuvant only. The total 
volume of a single vaccine dose was 100 μ l of which 50 μ l was given subcutaneously to each inguinal 
region/flank. After three vaccine doses, the mice were challenged with 100 S. mansoni cercariae per 
mouse. Perfusion of the mice occurred seven weeks after cercarial challenge. In the first vaccine trial, the 
proteins for all three candidates were insoluble. A repeat vaccine trial was conducted using only soluble 
and insoluble Sm-LAMP.
One day prior to perfusion, grid cages were used to collect faecal samples from mice. Faecal samples 
were weighed and stored in 4% formalin until processed.
Blood (10 μ l) was obtained from each mouse by tail bleed before the commencement of the vaccine 
trial and again before the cercarial challenge. Each blood sample was diluted with 90 μ l of PBS. The 
serum was separated, aliquoted, and stored at − 80 °C until required.
Mice were perfused as previously reported14,65 and the numbers of worm pairs and single males noted, 
and stored in 4% formalin for subsequent morphological assessment. A portion of mouse liver was stored 
in 4% (v/v) formalin for histological analysis of granuloma volume, while the rest was weighed and 
stored in dry tubes at − 20 °C for egg counts. Formalin fixed mouse livers were used for the preparation 
of Haematoxylin and Eosin (H&E) stained sections after paraffin embedding for histological analysis of 
granulomas. H &E sections were scanned using the Aperio slide scanner (Aperio, Germany) and the 
liver granuloma density was quantified using the Aperio Imagescope v11.1.2.760 software as described 
earlier66. The small intestine was dissected, cleaned and washed in PBS and 1 cm of the middle region 
of the small intestine dissected and pressed between a cover slip and a glass microscope slide to make 
oograms67 and examined on the same day to calculate the percentages of mature and immature eggs 
present. The remainder of the intestine was weighed and stored in a dry tube at − 20 °C for egg count-
ing. Faecal eggs counts per gram of faeces were calculated using standard methods14,68. Male and female 
worm lengths were measured in 10 worm pairs per each group using an Olympus CKX41 inverted 
microscope. Worm lengths from the vaccinated groups were compared with the control group to deter-
mine the effect of vaccination on worm growth and development.
Statistical analyses of vaccine data were performed using the Mann-Whitney U test. Percentage reduc-
tions in adult worm burden, female worm burden, and hepatic, intestinal and faecal egg burdens were 
calculated using the formula adopted previously69.
Serum collected from mice in control and vaccine groups after the completion of vaccination sched-
ule was tested for antibody titres of different immunoglobulin subtypes (IgG, IgG1, IgG2a, IgG2b and 
IgG3) using ELISA. Serial two fold dilutions were made from the 10× prediluted serum using block-
ing solution. Serum from the bleed before the first dose of vaccine was taken as the negative control. 
MaxiSorp® 96 well plates (Nunc) were coated with 0.5 μ g of protein per well overnight at 4 °C. Plates 
were blocked with 3% skim milk in 0.1% PBST for one hour at 37 °C. Two hundred microlitres (200 μ l) 
of serially diluted mouse serum from the vaccine trials (primary mouse antibodies) were added into cor-
responding wells. Plates were then incubated for one hour at 37 °C. After removing the primary antibody, 
plates were washed three times with 0.1% PBST and incubated with secondary anti mouse antibodies, 
IgG, IgG1, IgG2a, IgG2b and IgG3 (Invitrogen) diluted 1:2000, for 1 hour at 37 °C. SIGMAFAST™ OPD 
(o-phenylenediamine dihydrochloride) (Sigma) was used as the substrate and the absorption was read 
at 450 nm using a Bio Tek Synergy 4 plate reader.
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